Home  |  Contact

Cellosaurus Ramos (CVCL_0597)

Cell line name Ramos
Synonyms RAMOS; Ramos 1; RA 1; RA.1; Ra #1; Ra No. 1; Ramos(RA1); Ramos-RA1; Ramos (RA 1); Ramos (RA)
Accession CVCL_0597
Resource Identification Initiative To cite this cell line use: Ramos (RRID:CVCL_0597)
Comments Part of: MD Anderson Cell Lines Project.
Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel.
Characteristics: EBV-negative.
Doubling time: 20.4 +- 1.5 hours (PubMed=9225077); 14 hours (PubMed=20922763); ~48 hours (DSMZ).
Omics: Deep proteome analysis.
Omics: Deep RNAseq analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Derived from sampling site: Ascites.
Sequence variations TP53 p.Ile254Asp (c.760_761AT>GA) (PubMed=1915267; PubMed=2052620; PubMed=8344493).
HLA typing Source: PubMed=25960936
Class I
Class II
Disease Burkitt lymphoma (NCIt: C2912)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_KS64 (CellSensor ISRE-bla RA-1)CVCL_KS46 (CellSensor NFAT-bla RA-1)CVCL_KB47 (CellSensor NFkB-bla RA-1)
CVCL_KS55 (CellSensor STAT6-bla RA-1)CVCL_JL65 (Ramos B7)CVCL_2702 (Ramos-AW)
CVCL_X591 (Ramos-Blue)CVCL_X592 (Ramos-Blue KD-Myd)CVCL_C003 (Ramos-EHRA)
CVCL_2703 (Ramos-EHRB)CVCL_S546 (Ramos/DC-SIGN)CVCL_1646 (Ramos.2G6.4C10)
Sex of cell Male
Age at sampling 3Y
Category Cancer cell line
STR profile Source(s): ATCC; COG; DSMZ; ECACC; JCRB; KCLB; PubMed=20922763; PubMed=25877200

Penta D10,13
Penta E8,21
Web pages http://www.cells-talk.com/index.php/page/copelibrary?key=Ramos

PubMed=181343; DOI=10.1159/000149930
Klein G., Giovanella B.C., Westman A., Stehlin J.S. Jr., Mumford D.M.
An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection.
Intervirology 5:319-334(1975)

PubMed=7316467; DOI=10.1111/j.1469-1809.1980.tb00953.x
Povey S., Jeremiah S., Arthur E., Steel M., Klein G.
Differences in genetic stability between human cell lines from patients with and without lymphoreticular malignancy.
Ann. Hum. Genet. 44:119-133(1980)

Benjamin D., Magrath I.T., Maguire R.T., Janus C., Todd H.D., Parsons R.G.
Immunoglobulin secretion by cell lines derived from African and American undifferentiated lymphomas of Burkitt's and non-Burkitt's type.
J. Immunol. 129:1336-1342(1982)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

Farrell P.J., Allan G.J., Shanahan F., Vousden K.H., Crook T.
p53 is frequently mutated in Burkitt's lymphoma cell lines.
EMBO J. 10:2879-2887(1991)

PubMed=2052620; DOI=10.1073/pnas.88.12.5413
Gaidano G., Ballerini P., Gong J.Z., Inghirami G., Neri A., Newcomb E.W., Magrath I.T., Knowles D.M., Dalla-Favera R.
p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.
Proc. Natl. Acad. Sci. U.S.A. 88:5413-5417(1991)

PubMed=8316623; DOI=10.2307/3578190
Evans H.H., Ricanati M., Horng M.-F., Jiang Q., Mencl J., Olive P.
DNA double-strand break rejoining deficiency in TK6 and other human B-lymphoblast cell lines.
Radiat. Res. 134:307-315(1993)

Bhatia K., Goldschmidts W., Gutierrez M.I., Gaidano G., Dalla-Favera R., Magrath I.T.
Hemi- or homozygosity: a requirement for some but not other p53 mutant proteins to accumulate and exert a pathogenetic effect.
FASEB J. 7:951-956(1993)

Jain V.K., Judde J.-G., Max E.E., Magrath I.T.
Variable IgH chain enhancer activity in Burkitt's lymphomas suggests an additional, direct mechanism of c-myc deregulation.
J. Immunol. 150:5418-5428(1993)

Bae I., Fan S., Bhatia K., Kohn K.W., Fornace A.J. Jr., O'Connor P.M.
Relationships between G1 arrest and stability of the p53 and p21Cip1/Waf1 proteins following gamma-irradiation of human lymphoma cells.
Cancer Res. 55:2387-2393(1995)

Chapman C.J., Zhou J.X., Gregory C.D., Rickinson A.B., Stevenson F.K.
VH and VL gene analysis in sporadic Burkitt's lymphoma shows somatic hypermutation, intraclonal heterogeneity, and a role for antigen selection.
Blood 88:3562-3568(1996)

PubMed=9225077; DOI=10.1016/S0145-2126(97)00126-4
Okano M.
High susceptibility of an Epstein-Barr virus-converted Burkitt's lymphoma cell line to cytotoxic drugs.
Leuk. Res. 21:469-471(1997)

Klangby U., Okan I., Magnusson K.P., Wendland M., Lind P., Wiman K.G.
p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a mRNA and protein expression in Burkitt's lymphoma.
Blood 91:1680-1687(1998)

Gutierrez M.I., Cherney B., Hussain A., Mostowski H., Tosato G., Magrath I.T., Bhatia K.
Bax is frequently compromised in Burkitt's lymphomas with irreversible resistance to Fas-induced apoptosis.
Cancer Res. 59:696-703(1999)

PubMed=12967475; DOI=10.1111/j.1349-7006.2003.tb01518.x
Maesako Y., Uchiyama T., Ohno H.
Comparison of gene expression profiles of lymphoma cell lines from transformed follicular lymphoma, Burkitt's lymphoma and de novo diffuse large B-cell lymphoma.
Cancer Sci. 94:774-781(2003)

PubMed=20922763; DOI=10.1002/pbc.22801
Kang M.H., Smith M.A., Morton C.L., Keshelava N., Houghton P.J., Reynolds C.P.
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.
Pediatr. Blood Cancer 56:239-249(2011)

PubMed=22885699; DOI=10.1038/nature11378
Schmitz R., Young R.M., Ceribelli M., Jhavar S., Xiao W., Zhang M., Wright G., Shaffer A.L., Hodson D.J., Buras E., Liu X., Powell J., Yang Y., Xu W., Zhao H., Kohlhammer H., Rosenwald A., Kluin P., Muller-Hermelink H.K., Ott G., Gascoyne R.D., Connors J.M., Rimsza L.M., Campo E., Jaffe E.S., Delabie J., Smeland E.B., Ogwang M.D., Reynolds S.J., Fisher R.I., Braziel R.M., Tubbs R.R., Cook J.R., Weisenburger D.D., Chan W.C., Pittaluga S., Wilson W., Waldmann T.A., Rowe M., Mbulaiteye S.M., Rickinson A.B., Staudt L.M.
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.
Nature 490:116-120(2012)

PubMed=25960936; DOI=10.4161/21624011.2014.954893
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:E954893-E954893(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

Cell line collections ATCC; CRL-1596
BCRC; 60252
ECACC; 85030802
ECACC; 91030710
KCLB; 21596
NCBI_Iran; C128
NIH-ARP; 9938-10
Cell line databases/resources CLDB; cl4096
CLDB; cl4097
CLDB; cl4098
CCRID; 3111C0001CCC000047
CCRID; 3111C0001CCC000048
CCRID; 3111C0002000000052
CGH-DB; 9205-4
LINCS_HMS; 50811
Lonza; 725
Ontologies BTO; BTO:0003079
CLO; CLO_0008738
CLO; CLO_0008739
EFO; EFO_0002077
MCCL; MCC:0000410
Biological sample resources BioSample; SAMN01821590
BioSample; SAMN01821657
BioSample; SAMN03472718
Chemistry resources ChEMBL-Cells; CHEMBL3307664
ChEMBL-Targets; CHEMBL614629
Gene expression databases ArrayExpress; E-MTAB-2706
GEO; GSM987747
GEO; GSM987748
GEO; GSM987749
GEO; GSM99388
GEO; GSM1374843
GEO; GSM1374844
Other Wikidata; Q54949198
Polymorphism and mutation databases Cosmic; 929817
Cosmic; 931111
Cosmic; 991547
Cosmic; 998719
Cosmic; 1037704
Cosmic; 1226864
Cosmic; 1509204
Cosmic; 1517660
Cosmic; 1762459
Cosmic; 1818347
Proteomic databases PRIDE; PXD000447